Hamilton Wealth LLC Purchases 38,916 Shares of Guardant Health, Inc. $GH

Hamilton Wealth LLC boosted its holdings in Guardant Health, Inc. (NASDAQ:GH) by 103.0% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 76,700 shares of the company’s stock after purchasing an additional 38,916 shares during the quarter. Hamilton Wealth LLC’s holdings in Guardant Health were worth $7,085,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in Guardant Health by 2.1% in the 4th quarter. Vanguard Group Inc. now owns 12,160,768 shares of the company’s stock worth $1,242,101,000 after acquiring an additional 251,939 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Guardant Health by 33.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock valued at $575,670,000 after acquiring an additional 1,414,441 shares during the period. Franklin Resources Inc. grew its holdings in Guardant Health by 14.9% during the 4th quarter. Franklin Resources Inc. now owns 3,361,547 shares of the company’s stock valued at $343,348,000 after purchasing an additional 435,232 shares during the last quarter. Geode Capital Management LLC raised its position in Guardant Health by 9.4% in the 4th quarter. Geode Capital Management LLC now owns 3,213,657 shares of the company’s stock worth $328,297,000 after purchasing an additional 277,001 shares during the period. Finally, Fuller & Thaler Asset Management Inc. lifted its stake in Guardant Health by 3.0% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 2,441,730 shares of the company’s stock worth $249,398,000 after purchasing an additional 72,162 shares during the last quarter. Institutional investors own 92.60% of the company’s stock.

Insiders Place Their Bets

In other Guardant Health news, Director Musa Tariq sold 1,951 shares of the business’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $131.16, for a total transaction of $255,893.16. Following the transaction, the director owned 11,048 shares of the company’s stock, valued at approximately $1,449,055.68. The trade was a 15.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Myrtle S. Potter sold 1,556 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $131.16, for a total transaction of $204,084.96. Following the completion of the sale, the director directly owned 20,971 shares of the company’s stock, valued at $2,750,556.36. This represents a 6.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 708,565 shares of company stock valued at $90,556,597. Insiders own 5.60% of the company’s stock.

Guardant Health Stock Performance

NASDAQ:GH opened at $144.23 on Thursday. Guardant Health, Inc. has a fifty-two week low of $40.35 and a fifty-two week high of $174.08. The stock has a market capitalization of $19.12 billion, a PE ratio of -42.55 and a beta of 1.59. The company has a fifty day moving average of $141.90 and a two-hundred day moving average of $112.74.

Analyst Ratings Changes

GH has been the subject of several research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Guardant Health in a research report on Friday, July 17th. Mizuho lifted their target price on Guardant Health from $135.00 to $175.00 and gave the company an “outperform” rating in a research note on Monday, June 8th. Barclays lifted their price target on shares of Guardant Health from $120.00 to $150.00 and gave the stock an “overweight” rating in a report on Wednesday, June 24th. JPMorgan Chase & Co. upped their target price on Guardant Health from $130.00 to $135.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Finally, Royal Bank Of Canada assumed coverage on shares of Guardant Health in a report on Thursday, June 11th. They issued an “outperform” rating and a $185.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $160.04.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.